← Back to Search

Monoclonal Antibodies

Eptinezumab for Migraine (EVEC Trial)

Phase 4
Waitlist Available
Research Sponsored by H. Lundbeck A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 24
Awards & highlights

EVEC Trial Summary

This trial will compare eptinezumab to other advanced preventive medications in adults with episodic or chronic migraine in a real-world setting. The objective is to explore the comparative effectiveness on patient reported outcomes.

Eligible Conditions
  • Migraine

EVEC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline in Patient-informed Most Bothersome Symptom (PI-MBS) Score
Change From Baseline in Quality of Life (QOL) as Measured by the 5 Level Euro Quality of Life 5 Dimensional Questionnaire (EQ-5D-5L)
Health Care Resources Utilization (HCRU)
+5 more

Side effects data

From 2020 Phase 3 trial • 485 Patients • NCT04152083
2%
Hypersensitivity
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Eptinezumab

EVEC Trial Design

3Treatment groups
Experimental Treatment
Group I: Onabotulinumtoxin-AExperimental Treatment1 Intervention
Onabotulinumtoxin-A will be administered via intramuscular (IM) injection on Day 0 and Day 84.
Group II: EptinezumabExperimental Treatment1 Intervention
Participants will receive eptinezumab via intravenous (IV) infusion on Day 0 and Day 84.
Group III: Anti-CGRP injectablesExperimental Treatment3 Interventions
Participants are free to select treatment from one of 3 calcitonin gene-related peptide (CGRP) inhibitors: erenumab, fremanezumab, or galcanezumab. CGRP inhibitors will be administered via subcutaneous (SC) injection on Day 0 and then, per product label.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Galcanezumab
FDA approved
Fremanezumab
FDA approved
Eptinezumab
FDA approved
Erenumab
FDA approved

Find a Location

Who is running the clinical trial?

H. Lundbeck A/SLead Sponsor
325 Previous Clinical Trials
77,551 Total Patients Enrolled
12 Trials studying Migraine
4,754 Patients Enrolled for Migraine
Email contact via H. Lundbeck A/SStudy DirectorLundbeckClinicalTrials@Lundbeck.com
188 Previous Clinical Trials
58,308 Total Patients Enrolled
11 Trials studying Migraine
4,256 Patients Enrolled for Migraine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you please elucidate the level of security associated with Eptinezumab?

"The safety of eptinezumab has been established in a Phase 4 trial, thus it was assigned the maximum score of 3."

Answered by AI

Is the clinical trial being conducted in numerous locations within America?

"This clinical trial is currently signing up patients out of 10 separate sites, with 3 being located in Durham, North Kansas City and Palmetto Bay. It would be wise to choose the site nearest you so as to minimize your travel commitments if accepted into the study."

Answered by AI

How many research subjects are involved in this clinical experiment?

"This research project necessitates the recruitment of 200 participants that comply with the study's inclusion criteria. H. Lundbeck A/S is sponsoring this trial and will be using Carolina Women's Research and Wellness Center in Durham, North carolina as well as North Kansas City Hospital in Missouri to carry it out."

Answered by AI

Are there still opportunities to join this research project?

"This clinical trial is actively recruiting patients, as reported on the official website. It was opened to participants on March 4th 2022 and underwent its latest modification on November 9th same year."

Answered by AI

Who else is applying?

What state do they live in?
Louisiana
How old are they?
18 - 65
What site did they apply to?
The Headache Center
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Real World Effectiveness of Eptinezumab in Participants With Migraine
2022. "Real World Effectiveness of Eptinezumab in Participants With Migraine". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05284019.
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top